Study of vonicog alfa in children with von Willebrand disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be younger than 18 years old.
- You must have von Willebrand disease (vWD), a condition that makes it hard for your blood to clot.
- You must be receiving vonicog alfa (rVWF) to treat or prevent bleeding during surgery or a bleeding event.
- You must have been prescribed or given rVWF after it was approved for children in Japan.
- You cannot be taking part in any other clinical trial for rVWF.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This Phase 3 trial tests an recombinant version of the von Willebrand factor (rVWF) for people with severe von Willebrand disease (VWD) living in China. It aims to see if the drug can safely control bleeding and help those who need regular clotting factor treatments.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
Hear when a new Von Willebrand Disease (VWD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.